Q-omics provides the consensus-scored TNFRSF11B profile across patient tissues and cancer cell-line models. TNFRSF11B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF11B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TNFRSF11B RNA expression shows 17,440 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TNFRSF11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF11B survival associations across molecular data types. TNFRSF11B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF11B RNA expression–survival associations across cancer types. High TNFRSF11B expression shows unfavorable associations in STAD, UVM and CESC, but favorable associations in KIRC, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TNFRSF11B RNA expression.
This table summarizes TNFRSF11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF11B shows lower tumor expression in THCA, KIRC, KICH and LUSC and higher tumor expression in COAD and HNSC. The THCA box plot shows higher TNFRSF11B RNA expression in normal versus tumor tissue (log2 FC = −3.775, t-test p < 0.001).
This table shows molecular features associated with TNFRSF11B in patient tissues and cancer cell lines. In patient samples, TNFRSF11B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
